Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Mescaline/Palliative & End-of-Life Distress

Mescaline for Palliative & End-of-Life Distress

4 papers and 0 clinical trials exploring mescaline as a treatment for palliative & end-of-life distress.

CompoundPhenethylamine

Mescaline

A naturally occurring phenethylamine psychedelic found in certain cacti, investigated for its role in religious practice and psychiatric research.

Full Mescaline profile
IndicationApproximately 40% of patients with terminal illnesses report significant distress at the end of life.

Palliative & End-of-Life Distress

Palliative and end-of-life distress represents a significant psychosocial challenge faced by patients with life-limiting illnesses, significantly impacting quality of life. Recent research suggests that psychedelic compounds, particularly psilocybin, may offer promising therapeutic benefits in alleviating existential distress and improving psychological well-being in these patients.

Full Palliative & End-of-Life Distress profile

Academic Research

4 papers
Open Accessindividual

Hopelessness, Suicidality, and Co-Occurring Substance Use among Adolescent Hallucinogen Users-A National Survey Study

Analysing nationally representative YRBSS data from 2001–2019 (125,550 students), 8.4% of adolescents reported lifetime hallucinogen use, declining from 13.3% to 7.0% over the period. Hallucinogen users had significantly higher odds of feeling sad or hopeless, suicidal ideation and planning, and markedly greater co‑occurring use of alcohol, tobacco, cannabis and other illicit drugs.

Published
December 5, 2022
Journal
Children
Authors
Desai, S., Jain, V., Xavier, S., Du, W.
Paywallmeta

Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function

This comprehensive review (2019) by some of the leading researchers in psychedelics looks at both the epidemiological & clinical studies and the positive (and negative) effect that psychedelics can have.

Published
May 1, 2019
Journal
Pharmacology and Therapeutics
Authors
Johnson, M. W., Hendricks, P. S., Barrett, F. S., Griffiths, R. R.
Open Accessmeta

Psychedelics

This paper is the most comprehensive review of psychedelics research up to 2016 by the eminent David E. Nichols.

Published
April 1, 2016
Journal
Pharmacological Reviews
Authors
Nichols, D. E.
Open Accessindividual

Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer

This is the first (modern) double-blind placebo-controlled study (n=12) of psilocybin (14mg/70kg) for the treatment of (end-of-life) anxiety (and depression) related to cancer. Treatment led to a significant reduction in anxiety symptoms up to three months after treatment and improvements in depressive symptoms reached significance after six months.

Published
January 3, 2011
Journal
JAMA Psychiatry
Authors
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., Greer, G. R.

Clinical Trials

0 trials

No clinical trials have been tagged with both Mescaline and Palliative & End-of-Life Distress yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all Mescaline papers Search all Palliative & End-of-Life Distress trials Full Mescaline profile Full Palliative & End-of-Life Distress profile